{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-050236","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.357310+00:00","generated_at":"2026-06-10T07:44:10.276442+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts","bullets":["FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.","Over 5,000 KidneyIntelX tests performed in FY2023, up 55% from prior year.","Reduced annual operating expenses by over $11M vs prior year; additional cuts underway.","Completed $20.3M equity financing in February 2023 led by new institutional investors.","Secured multiple insurance contracts including EmblemHealth and CareFirst; over 40 commercial payors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-050236","json":"https://secwatch.observer/filing/0000950170-23-050236.json","markdown":"https://secwatch.observer/filing/0000950170-23-050236.md","text":"https://secwatch.observer/filing/0000950170-23-050236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/0000950170-23-050236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/rnlx-20230928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:44:10.276442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe91d193b7318b26e88e9ca48576bff511a4a899","claim":"Renalytix plc reported financial results for the fiscal year ended June 30, 2023.","evidence_excerpt":"Renalytix plc (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023050236/0000950170-23-050236-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}